NOAC Studies in VTE AF Studies Superior Outcomes.

Slides:

Advertisements

Similar presentations

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

Advertisements

Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,

2014 ESC guidelines update on the diagnosis and management of acute pulmonary embolism Anticoagulation for the treatment of PE and secondary prevention.

CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease.

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Addressing the Challenges in Primary and Secondary Stroke Prevention

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

NOACs for Cancer-Associated Thrombosis:

Anticoagulants in Interventional Cardiology:

Extended Treatment of VTE: Who is the Right Candidate?

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

NOACs In Long-term VTE Treatment: A State Of The Art Review

Long-Term Treatment of VTE: Case Studies

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

UNDERSTANDING RISK STRATIFICATION IN PAH:

NOACs in Clinical Practice: Are They All the Same?

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Case Challenge: Anticoagulant Choices for Acute PE

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

New Oral Anticoagulants and VTE Management

Real-World Safety of NOACs: What Do We Know Today?

VTE Treatment Conventional Approach

Efficacy and Safety of Edoxaban in Patients With AF and HF

TAVR and the Risk of Thrombosis

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Real-World Evidence in VTE

Dos and Don’ts for High-Risk Elderly Patients With AF

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Pulmonary Embolism /Pulmonary hypertension

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Anticoagulation and Thrombosis Management

Identifying High-Risk AF Patients

Long-Term Treatment of VTE: Case Studies

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

Extraordinary Cases in VTE

Program Goals Background: Anticoagulation in Patients With VTE.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Disease Burden of VTE Phases of VTE Treatment.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

At the Crossroads of Coagulation

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

NOAC Studies in VTE

AF Studies Superior Outcomes

Meta-analysis VTE Studies Safety Outcomes Favor NOACs vs VKA

Hokusai

What’s New in the 2014 ESC PE Guidelines?

Prognostic Assessment of Patients With Acute PE

Acute PE: Based on Early (intermediate) Mortality Risk Risk Parameters and Scores

ESC 2014 PE Anticoagulation Recommendations

Extended Treatment of VTE With NOACs

ESC 2014 Guideline Recommendations for Extended Treatment Using NOACs

Chronic Thromboembolic Pulmonary Hypertension

Recommendations for the Management of PE in Pregnancy and PE in Patients With Cancer